Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
April 12 2021 - 7:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo,
today announced the appointment of Georgia Keresty, Ph.D.,
M.P.H., to the company’s Board of
Directors.
“Dr. Keresty's
experience as a scientific and
operational leader in our industry will be a great
asset to Intellia as we continue to advance our research
programs, expand our manufacturing capabilities and move
towards delivering potentially curative therapies
to patients globally,” said Intellia President and
Chief Executive Officer John Leonard, M.D.
Dr. Keresty brings more than 35 years of pharmaceutical industry
experience to Intellia’s board, including leading the transition of
novel therapeutic programs from preclinical to clinical
development, and process development to commercial manufacturing.
During her career, she has held key global roles in pharmaceutical
research and development, operations, manufacturing and
distribution, quality, compliance and regulatory affairs. Dr.
Keresty recently served as chief operating officer and global head,
medical sciences and development operations for Takeda Research and
Development, a division of Takeda Pharmaceuticals USA, Inc. Prior
to joining Takeda, Dr. Keresty served in leadership roles at
Johnson & Johnson, including as vice president and global
head, pharmaceutical development and manufacturing science; at
Bristol-Myers Squibb Co., as vice president, worldwide quality and
compliance; and at Novartis Pharmaceuticals Corporation as
manufacturing site head.
In addition to Intellia’s board, Dr. Keresty serves as a
member of the board of directors of Aspen Technology, Inc.,
(NASDAQ: AZPN), an industrial asset optimization software company
and Solid Biosciences, Inc., (NASDAQ: SLDB), a life science
company. She is also a member of the board of directors of
Commissioning Agents, Inc., a global engineering services firm, and
the board of trustees for Clarkson University in Potsdam, New York.
She previously served on the board of Janssen Alzheimer
Immunotherapy and the board of trustees for the New Jersey
Foundation for Aging, which is now called the NJ Advocates for
Aging Well.
Dr. Keresty earned B.Sc. degrees in Chemical Engineering from
Clarkson University and Computer Science from Ramapo College, an
M.S. in Information Systems from Pace University, an M.B.A. and
Ph.D. in Operations Management from Rutgers Business School, and an
M.P.H. in Global Health Leadership from the University of Southern
California.
About Intellia Therapeutics Intellia
Therapeutics is a leading clinical-stage genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
both producing therapeutics that permanently edit and/or correct
disease-associated genes in the human body with a single treatment
course, and creating enhanced engineered cells that can treat
oncological and immunological
diseases. Intellia’s combination of deep
scientific, technical and clinical development
experience, along with its leading intellectual property portfolio,
puts it in a unique position to unlock broad therapeutic
applications of the CRISPR/Cas9 technology and create new classes
of therapeutic products. Learn more about Intellia and CRISPR/Cas9
at intelliatx.com. Follow us on Twitter @intelliatweets.
Forward-Looking Statements This press
release contains “forward-looking statements” of Intellia
Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our CRISPR/Cas9 intellectual property
portfolio; achieve stable or effective genome editing; the timing
and potential achievement of milestones to advance our pipeline and
grow as a company; and the anticipated contribution of the members
of our board of directors and our executives to our operations and
progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed, manufactured and commercialized; the risk
that the results of preclinical studies or clinical studies will
not be predictive of future results in connection with future
studies; the risk that Intellia may not be able to meet or comply
with applicable laws and regulations, including clinical,
manufacturing and commercialization requirements; and the risk that
Intellia’s collaborations with Novartis Institutes for BioMedical
Research, Inc. or Regeneron Pharmaceuticals, Inc. or its
other ex vivo collaborations will not continue or will
not be successful. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with
the Securities and Exchange Commission (“SEC”). All
information in this press release is as of the date of the release,
and Intellia undertakes no duty to update this information unless
required by law.
Intellia Contacts:
Investors:Lina LiDirectorInvestor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Julie
FergusonInterim Head of External Affairs &
Communications+1-312-385-0098julie.ferguson@intelliatx.com
Aspen Technology (NASDAQ:AZPN)
Historical Stock Chart
From May 2024 to Jun 2024
Aspen Technology (NASDAQ:AZPN)
Historical Stock Chart
From Jun 2023 to Jun 2024